Gibson Dunn Advises Arrowhead Pharmaceuticals on Asset Purchase Agreement Between Sanofi and Visirna Therapeutics
Gibson Dunn is representing Arrowhead Pharmaceuticals in an asset purchase agreement between its subsidiary, Visirna Therapeutics, and Sanofi.